DWTX — Dogwood Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1818844 ·
Last close
$1.08
Market Cap
$41.29M
52W High
$7.04
52W Low
$0.90
ADV30
97,623
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 100,000 11,896 -4,917,300 -4,882,942 75,608,219 4,948,266 11,475,000
Jun 2026 0 — -4,872,628 -11,529,609 80,495,480 9,610,033 12,129,372
Mar 2026 0 — -5,076,366 -4,986,614 95,207,871 13,227,839 14,584,519
Dec 2025 0 — -3,806,279 -3,780,449 90,171,237 6,524,744 15,274,370

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-15,108,253
Investing CF
—
Financing CF
$11,323,909
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-8.95
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-124,592,539
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-29,564,398
Pretax Income TTM
$-38,490,384
Interest Exp TTM
—
Analysts
3

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -27,968,445 -34,257,370 90,171,237 15,274,370 74,896,867 -15,618,651
Dec 2024 0 -12,227,248 -12,349,724 94,308,246 30,027,223 64,281,023 -8,790,805
Dec 2023 0 -5,446,919 -5,296,015 4,165,442 358,548 3,806,894 -4,870,489
Dec 2022 0 -12,315,309 -12,247,834 8,369,756 1,043,262 7,326,494 -11,467,797

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-36,041,288
OpCashFlow TTM
—
Assets (Latest)
$80,495,480
Forward EPS
$-6.37

Peers — same industry

TickerNameMarket CapLastDaily %
TLPH TALPHERA, INC. $41.61M $0.80 —
PLRX PLIANT THERAPEUTICS, INC. $40.93M $0.66 —
ALDX Aldeyra Therapeutics, Inc. $41.88M $0.69 —
ELTX Elicio Therapeutics, Inc. $40.48M $1.43 —
ATNM Actinium Pharmaceuticals, Inc. $42.45M $1.35 —

News headlines (Yahoo Finance, 1h cache)

Dogwood Announces $5 Million Private Placement with CK Life Sciences Int’l., (Holdings) Inc.
2026-10-19 12:30 · Yahoo
Dogwood to Participate in the 2026 Maxim Growth Summit
2026-10-06 12:45 · Yahoo
Dogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b Trial
2026-09-14 12:45 · Yahoo
Dogwood Therapeutics Nears Phase 2b Readout for Halneuron Neuropathic Pain Treatment
2026-09-01 22:01 · Yahoo
Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026
2026-08-17 12:30 · Yahoo
Dogwood Therapeutics Announces Second Quarter 2026 Financial Results
2026-08-13 12:30 · Yahoo
Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026
2026-07-20 12:30 · Yahoo
Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board
2026-06-30 12:45 · Yahoo
Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy
2026-04-15 13:00 · Yahoo
Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M
2026-04-23 13:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.